Encouraging Results Seen in Patients with Heavily Pre-Treated Low-Grade Serous Ovarian-Late-Breaking Abstract Oral Presentation

Video Transcription

Video Summary

The speaker presents interim results from the RAMP 201 study on the treatment of low-grade serous ovarian cancer. This type of cancer is distinct from high-grade serous disease and is driven by MAP kinase pathway alterations. The combination of avutametinib and dafactinib showed promising results in a prior study, leading to the Phase 2 RAMP 201 study. The study enrolled women with recurrent low-grade serous ovarian cancer who had received prior chemotherapy. The combination treatment resulted in an objective response rate of 45%, regardless of the number of prior lines of therapy. The combination was well-tolerated, and based on these results, a Phase 3 study called RAMP 301 will be initiated.

Asset Subtitle

Watch Dr. Rachel Grisham's late-breaking abstract oral presentation for EFFICACY AND SAFETY OF AVUTOMETINIB + DEFACTINIB IN RECURRENT LOW-GRADE SEROUS OVARIAN CANCER FOLLOWING PRIOR SYSTEMIC THERAPY

Keywords

RAMP 201 study

low-grade serous ovarian cancer

MAP kinase pathway alterations

avutametinib

dafactinib